LumiThera, Inc. Inc. have announced their recent merger of Diopsys. LumiThera are a commercial stage medical device company offering photobiomodulation treatment for ocular damage and disease. With this acquisition, they find themselves merging with a leader in modern visual electrophysiology medical devices. "We are strong believers of treating degenerative disease early to slow the progression of vision-threatening disease. The synergy of these technologies makes sense on many levels and could optimize Valeda treatments" Clark Tedford, LumiThera, Inc. CEO.
In other news, Alcon previously entered the #glaucoma treatment market, but had to withdraw their product, CyPass Micro-Stent from the market due to safety concerns. Now they have found a new glaucoma treatment to acquire; Hydrus Microstent by Ivantis, Inc. The Hydrus device was approved by the FDA in 2018 and is about the size of an eyelash. It is implanted in Schlemm’s canal in a minimally invasive surgical procedure. In a five-year study of the Hydrus Microstent, patients who received the device experienced a 60% reduction in the need for secondary invasive glaucoma surgeries. “Our global commercial footprint and development capabilities make us well positioned to build on the success of Ivantis and help even more patients see brilliantly with Hydrus Microstent.” David Endicott, Alcon CEO.
James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.